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In symptomatic patients with acute Coronavirus disease 2019 (COVID-19),
lymphocytopenia is one of the most prominent laboratory findings. However, to date
age and gender have not been considered in assessment of COVID-19-related cell
count alterations. In this study, the impact of COVID-19 as well as age and gender on
a large variety of lymphocyte subsets was analyzed in 33 COVID-19 patients and
compared with cell counts in 50 healthy humans. We confirm that cell counts of total
lymphocytes, B, NK, cytotoxic and helper T cells are reduced in patients with severe
COVID-19, and this tendency was observed in patients with moderate COVID-19.
Decreased cell counts were also found in all subsets of these cell types, except for
CD4+ and CD8+ effector memory RA+ (EMRA) and terminal effector CD8+ cells.
In multivariate analysis however, we show that in addition to COVID-19, there is an
age-dependent reduction of total, central memory (CM), and early CD8+ cell subsets,
as well as naïve, CM, and regulatory CD4+ cell subsets. Remarkably, reduced naïve
CD8+ cell counts could be attributed to age alone, and not to COVID-19. By con-
trast, decreases in other subsets could be largely attributed to COVID-19, and only
partly to age. In addition to COVID-19, male gender was a major factor influencing
lower counts of CD3+ and CD4+ lymphocyte numbers. Our study confirms that cell
counts of lymphocytes and their subsets are reduced in patients with COVID-19, but
that age and gender must be considered when interpreting the altered cell counts.
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1 | INTRODUCTION
Coronavirus Disease 2019 (COVID-19) is a high contagious acute
respiratory tract infection caused by the severe acute respiratory
syndrome coronavirus type 2 (SARS-CoV-2) that emerged in China in
late 2019.1 Most people infected with SARS-CoV-2 are asymptomatic
or have mild to moderate disease with fever, cough, or myalgia, and
recover quickly. Especially older humans and patients with com-
orbidities have an increased risk of developing pneumonia and fatal
acute respiratory distress syndrome (ARDS) or sepsis.2–4 The injury of
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the respiratory system is thought to be mediated by the virus itself
and/or an overstimulated immune system.5 COVID-19 is associated
with various lab abnormalities of coagulation, inflammatory bio-
markers, and biochemical as well as hematologic values dependent on
the severity of COVID-19.6 The most striking finding in the blood
count of patients with COVID-19 is lymphocytopenia that correlates
with the severity of disease.7, 8 However, interpretation of virus-
induced alterations of lymphocyte counts should also be considered
in the light of age, given that COVID-19 patients mostly belong to the
middle-aged and old population. A large basic effect of aging is seen
on counts of cytotoxic and helper T cells. During the human lifetime,
the proportion of naïve T cells within both CD4+ and CD8+ cells
decreases dramatically from 45% and 43% to 20% and 10%, respec-
tively.9 In contrast, the proportion of central memory and effector
memory cells within cytotoxic and helper T lymphocytes increases
with age. Furthermore, also gender has an impact on lymphocyte
counts. In general, counts of total CD3+ T lymphocytes as well as
CD8+ cytotoxic T cells and especially CD4+ T helper cells are higher
in females compared to males.10 Thus, the question arises whether
the widely reported alterations in counts of lymphocytes and their
subsets in patients with COVID-19 are indeed primarily due to coro-
navirus infection, or whether gender and age might have a significant
impact.
While lymphocytopenia in COVID-19 patients is well known, the
influence of age and gender has hardly been considered so far.
The aim of this study was to analyze the influence of age and gender
on the total number of lymphocytes, as well as on B-, T- and NK-cell
subsets during COVID-19.
2 | PATIENTS AND METHODS
2.1 | Study population and trial design
Study participants with COVID-19 were recruited for this prospective
study at the University Medical Hospital, Augsburg, between April
and October 2020. Patients were included immediately after clinical
admission and confirmation of a positive qPCR test for SARS-CoV-2
from oropharyngeal swab. The time period between onset of COVID-
19 symptoms and study inclusion was restricted to a maximum of
28 days. Exclusion criteria were malignancy, immune deficiency, auto-
immune disorder, chronic infection disease, and pregnancy. Every
participant was classified according to interim guidance of the World
Health Organization (WHO) as mild infection (uncomplicated upper
respiratory tract infection), pneumonia (without need for supplemen-
tal oxygen), severe pneumonia (with need for supplemental oxygen),
acute respiratory distress syndrome (ARDS), sepsis, or septic shock.11
Patients suffering from severe pneumonia, ARDS, sepsis, or septic
shock were categorized as “severe” COVID-19 in our study, while all
other causes were defined as “moderate” COVID-19.
The study was performed in accordance with the revised declara-
tion of Helsinki and approved by the internal ethics committee (inter-
nal review board No. 2020-12). Signed informed consent was
obtained from all participants allowing analysis of all laboratory data
presented in this manuscript. Additionally, 50 healthy adult blood
donors from the blood bank at University Medical Hospital, Augsburg,
served as control group. Control samples were collected, measured,
and analyzed during the pre-COVID-19 era excluding infection with
SARS-CoV-2 as described below.
2.2 | Analysis of lymphocytes and their subsets
EDTA blood samples (EDTA-blood) were taken from patients and
processed within 24 h. Flow cytometry was used to identify and mea-
sure total counts of lymphocytes as well as B, T and NK cells and all
their subsets. B lymphocytes were identified by the presence of CD19
(CD19-PC7 IM3628) and were further divided into naïve (IgD+
CD27; IgD-FITC B30652, CD27-ECD B26603), non-class switched
(NCS) memory (IgD+ CD27+), class switched (CS) memory (IgD
CD27+) and transitional (CD24hi CD38hi; CD24-PE IM1428U,
CD38-PC5 A07780) subsets. T lymphocytes defined by positivity for
CD8 or CD4 were subdivided into naïve (CD62L+ CD45RA+), memory
T cells (CD4+ CD45RA CD45RO+/CD8+ CD45RA CD45RO+),
which were further divided into central memory (CD62L+ CD45RA),
effector memory (CD62L CD45RA), effector memory RA+ (EMRA)
(CD62L CD45RA+) and activated memory (HLA-DR+ or CD69+)
cells, and FoxP3+ cells. Furthermore, type 1, 2 and 17 CD4+ T helper
(Th1/Th2/Th17) cells were identified by using antibodies against
CXCR3, CCR4, CCR5 and CCR6. Th1 cells were defined as CD4+
CXCR3+ CCR4 CCR5+ CCR6, Th2 cells as CD4+ CXCR3
CCR4+ CCR5 CCR6 and Th17 cells as CD4+ CXCR3 CCR4+
CCR5 CCR6+. Within cytotoxic CD8+ T lymphocytes, activated
subsets in early (CD28+ CD27+), intermediate (CD28 CD27+) and
late (CD28 CD27) status as well as exhausted (CD279+) and ter-
minal effector (CD279 CD57+) cells were identified. CD56+ T cells
were defined as CD56+ CD3+. NK lymphocytes were detected as
CD56+ CD3 cells and subdivided into three NK subsets (CD56+
CD16+, CD56dim CD16bright, and CD56bright CD16dim). Detailed
information on lymphocyte subset specific immune phenotypes and
on fluorochrome-antibody conjugates are listed in Table S2. The gat-
ing strategy is shown in Figure S1 as already described by our
research group.12
2.3 | Statistical analysis
Results are given as median values with interquartile ranges for
descriptive analysis if not otherwise indicated. Wilcoxon test for uni-
variate analysis was used for all statistical tests (two-tailed) to detect
different numbers of analyzed lymphocyte subsets from patients with
moderate or severe COVID-19 compared with healthy control group
as well as analyzing effects of gender. Relative cell count deviations
were calculated per 10 years. Impact of age and gender on differences
in lymphocyte populations between COVID-19 patients and healthy
subjects was investigated using a fitted multivariate linear regression
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analysis. p-values < 0.05 were regarded as statistically significant.
Data were analyzed with SPSS 24.0 for Windows (SPSS Inc, Chicago,
IL), and R 4.0.2.
3 | RESULTS
3.1 | Population characteristics
The median age of 33 study participants was 71 years (range: 17–94),
and 12 were female and 21 male. One-third (11/33) of patients had
moderate COVID-19, and two-thirds of patients (22/33) were catego-
rized as having severe COVID-19. The time period between onset of
COVID-19 associated symptoms and the measurement of lymphocyte
counts and their subsets was 4 days (range: 1–24). A list of patient
characteristics including symptoms, and severity of illness are given in
Table 1. Healthy controls had comparable characteristics exept for
younger age of median 43 years (range: 18–81; p < 0.001) including
17 female and 33 male participants.
3.2 | Univariate analyses of lymphocyte
populations
COVID-19 patients with moderate and severe disease had lower total
lymphocyte counts (1120/μl and 730/μl, respectively) compared to
controls (1884/μl, p = 0.002 and p < 0.001, respectively). Patients
with severe COVID-19 had also reduced cell counts of total CD3+
cells (380/μl vs. 1175/μl, p ≤ 0.001), cytotoxic CD8+ cells (112/μl
vs. 292/μl, p ≤ 0.001) and CD4+ helper cells (209/μl vs. 782/μl,
p ≤ 0.001) and their subsets except of terminal effector CD8+ cells
and EMRA CD4+ and CD8+ cells, respectively. These alterations of
cell counts were also seen in the subpopulations of NK (81/μl
vs. 226/μl, p ≤ 0.001) and B (71/μl vs. 211/μl, p ≤ 0.001) cells and
their subsets. Similar trends were detected in patients with moderate
COVID-19 but without reaching significance in most subtypes of T
cells. Cell counts of all lymphocyte subsets are shown in Figure 1 and
listed in Table 2.
Age had an impact on total lymphocyte count and most subsets
in entire cohort of COVID-19 patients and healthy controls, as listed
in Table 3. Median numbers of total lymphocytes were reduced by
12.5% per 10 years (/10y; Figure 2A). This aging effect could be
observed also for CD3+ cells (14.1%/10y), CD8+ cells
(19.1%/10y; Figure 2B) and some of their subsets (naïve
(38.8%/10y; Figure 2C), memory (19.6%/10y), CM (21.1%/10y),
EM (18.3%/10y), early (29.5%/10y; Figure 2D), intermediate
(14.5%/10y), and exhausted CD8+ cells (9.6%/10y) as well
as for CD4+ cells (14.8%/10y) and some of their subsets
(naïve (21.5%/10y), memory (14.2%/10y), CM (16.0%/10y), EM
(13.0%/10y), regulatory (12.5%/10y), and Il2R+ CD4+ cells
(18.2%/10y)). Aging had also a negative influence on NK
cells (13.6% /10y) and their subsets (CD56+ CD16+ (13.4%/10y),
CD56dim CD16bright (17.8%/10y), CD56bright CD16dim
(19.0%/10y)), as well as on B cells (14.4%/10y) and their subsets
(naïve (23.4%/10y), memory non-class switch (24.0%/10y), mem-
ory class switch (10.8%/10y), transitional (79.3%/10y)).
Gender influenced the ratio of CD4/CD8 lymphocyte counts in
univariate analysis. Female participants had a higher median ratio
compared to male in study participants and healthy controls (2.89
(quartile: 1.85–3.94) vs. 2.06 (1.44–3.10); p = 0.024).
3.3 | Multivariate analyses of lymphocyte
populations
The impact of moderate/severe COVID-19, gender and increasing age
per 10-year timeframe on total count of lymphocytes and their sub-
sets was estimated using a linear regression model on log-transformed
cell counts, resulting in multiplicative factors (=coefficient [cB]) in a
multivariate model (Figure 3, Table S1).
Total lymphocyte count was decreased in moderate (cB: 0.640,
p = 0.008) and severe (cB: 0.427, p < 0.001) COVID-19 patients com-
pared to healthy controls, and this decrease was independent of age
and gender.
TABLE 1 Patient characteristics
Age [years]; median (range) 71 (17–94)
Gender
Male; n 21 (64%)
Female; n 12 (36%)
Symptoms type
Cough; n 18 (55%)
Dyspnea; n 17 (51%)
Fever (>38C); n 15 (46%)
Myalgia; n 14 (42%)
Sore throat; n 8 (24%)
Headache; n 5 (15%)
Diarrhea; n 3 (9%)
Dorsal pain; n 3 (9%)
Nausea; n 3 (9%)
Cardiovascular symptoms; n 3 (9%)
Loss of taste; n 2 (6%)
Emesis; n 2 (6%)
Thoracic pain; n 2 (6%)
Abdominal pain; n 1 (3%)
Dorsal pain; n 1 (3%)
Severity of COVID-19 (according to WHO)
Mild illness; n 7 (21%)
Pneumonia; n 4 (12%)
Severe pneumonia; n 10 (30%)
ARDS; n 12 (36%)
Treatment in intensive care unit; n 13 (39%)
Need for invasive ventilation; n 8 (24%)
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Total T cell populations (CD3+) were also lower in severe
COVID-19 (cB: 0.395, p < 0.001) patients but elevated by female-
gender (cB: 1.291, p = 0.033).
Cytotoxic T cells (CD8+) were found with lower levels in patients
with severe COVID-19 (cB: 0.472, p = 0.001), and this effect was
even more pronounced with increasing age (cB: 0.876, p = 0.004).
Subsets of CD8+ cells showed reduced counts within memory
(cB: 0.395, p = 0.003), effector memory (cB: 0.394, p = 0.003), early
(cB: 0.320 p < 0.001), intermediate (cB: 0.480, p = 0.010), exhausted
(cB: 0429, p < 0.001), and Il2R+ (cB: 0.380, p = 0.002) cell subsets in
severe COVID-19 patients, whereas early CD8+ cells were addition-
ally influenced by increasing age (cB: 0.793, p < 0.001). In patients
with moderate COVID-19, significant reduction of cell counts was
also detected for intermediate (cB: 0.427, p = 0.007) and Il2R+
(cB: 0.411, p = 0.014) cytotoxic T cells. Remarkably, numbers of naïve
CD8+ cells were not influenced by COVID-19 but were diminished
depending on age (cB: 0.584, p < 0.001) and increased in females
(cB: 1.773, p = 0.044). Central memory CD8+ cells were also diminished
depending on age (cB: 0.809, p = 0.011) as the only associated factor.
T helper cell (CD4+) counts were lower in patients with severe
COVID-19 (cB: 0.320, p < 0.001), and this cell population was higher
in females (cB: 1.363, p = 0.027). All analyzed cell counts of CD4+
subsets were reduced in severe COVID-19 patients (naïve (cB: 0.278,
p < 0.001), memory (cB: 0.326, p < 0.001), CM (cB: 0.477, p = 0.004),
EM (cB: 0.222, p < 0.001), EMRA (cB: 0.165, p = 0.002), THC1 (cB:
0.223, p < 0.001), THC2 (cB: 0.260, p < 0.001), THC17 (cB: 0.336,
p < 0.001), IlR2+ (cB: 0.540, p = 0.006), regulatory (cB: 0.346,
p < 0.001)). Similarly, cell counts of some of these subsets (memory
(cB: 0.624, p = 0.036), effector memory (cB: 0.492 p = 0.004), THC2
(cB: 0.433, p = 0.003), and regulatory cells (cB: 0.165, p = 0.002))
were also reduced in moderate COVID-19 patients. Female gender
was associated with higher numbers of naïve helper cells (cB: 1.647,
p = 0.012), and age with reduced numbers of naïve (cB: 0.882,
p = 0.020), CM (cB: 0.899, p = 0.049), and Il2R+ helper cells
(cB: 0.873, p = 0.004). By contrast, the numbers of EMRA cells were
increased depending on age (cB: 1.404, p = 0.005) and THC2
(cB: 1.111, p = 0.049).
CD3+ CD56+ T cells were found to be reduced in patients with
severe COVID-19 (cB: 0.431 p = 0.020) independent of age or
gender.
Total B cells were decreased in moderate (cB: 0.335, p < 0.001)
and severe (cB: 0.503 p = 0.004) COVID-19 patients. Numbers of
B cells in their defined subsets were also reduced in moderate
COVID-19 patients (naïve (cB: 0.219, p < 0.001), non-cs-memory
(cB: 0.202, p < 0.001), cs-memory (cB: 0.272, p < 0.001), transitional
(cB: 0.364, p = 0.002)), and such cells were similarly reduced in
severely affected patients (naïve (cB: 0.380, p = 0.005), non-cs-
memory (cB: 0.279, p < 0.001), cs-memory (cB: 0.256, p < 0.001),
transitional (cB: 0.388, p = 0.002)). The reduction of transitional B
cells was pronounced by aging (naïve (cB: 0.219, p < 0.001), non-cs-
memory (cB: 0.202, p < 0.001), cs-memory (cB: 0.272, p < 0.001),
transitional (cB: 0.862, p = 0.020)).
NK cell counts (cB: 0.499, p < 0.001) and counts of their subsets
(CD56+ CD16+ (cB: 0.480, p < 0.001), CD56 + bright CD16dim
(cB: 0.344, p = 0.014), CD56dim CD16bright were lower in patients
with severe COVID-19 only. An additional negative influence of aging
F IGURE 1 Distribution of counts of total lymphocytes and main subtypes are stratified by healthy controls (light gray), moderate COVID-19
(medium gray), and severe COVID-19 (dark gray) patients. Black lines and black points in boxplot represent median and mean values, respectively.
*p < 0.05 significant value
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TABLE 2 Lymphocyte and their subset in patients with light or severe COVID-19 compared to healthy controls. Cell counts are given as
median value/μl (interquartile range)





(interquartile range) (n = 50)
Median cell count
(interquartile range) (n = 11)
Median cell count
(interquartile range) (n = 22)
Total
lymphocytes
1884 (1439–2288) 1120 (867–1390) 0.002 730 (463–1043) 0.000 0.040
CD3+ cells 1175 (839–1675) 879 (576–971) 0.017 380 (263–547) 0.000 0.003
CD8+ cells 292 (209–488) 219 (118–354) 0.058 112 (71–179) 0.000 0.053
Naive 78 (44–138) 27 (20–124) 0.298 15 (7–35) 0.000 0.032
Memory 124 (65–164) 55 (48–86) 0.017 24 (17–66) 0.000 0.123
CM 35 (14–56) 16 (8–33) 0.163 8 (6–19) 0.002 0.204
EM 94 (56–139) 54 (30–62) 0.017 21 (14–49) 0.000 0.178
EMRA 51 (23–119) 24 (17–132) 0.528 45 (19–80) 0.374 0.749
Early 180 (154–291) 92 (55–152) 0.008 35 (19–54) 0.000 0.004
Intermediate 21 (13–34) 7 (4–26) 0.050 8 (5–14) 0.000 0.778
Late 51 (28–124) 27 (16–77) 0.159 58 (23–110) 0.816 0.396
Exhausted 86 (59–133) 53 (43–94) 0.196 36 (19–62) 0.000 0.044
Terminal
effector
24 (13–95) 16 (9–70) 0.431 24 (11–52) 0.494 0.985
Regulatory 0 (0–1) 0 (0–1) 0.616 0 (0–0) 0.022 0.336
Il2R+ 1 (0–1) 0 (0–0) 0.019 0 (0–0) 0.004 0.462
CD4+ cells 782 (554–993) 523 (388–554) 0.016 209 (113–277) 0.000 0.003
Naive 311 (191–411) 174 (142–318) 0.098 53 (29–110) 0.000 0.002
Memory 430 (323–608) 270 (168–402) 0.018 123 (77–184) 0.000 0.017
CM 272 (159–406) 154 (116–304) 0.149 81 (50–135) 0.000 0.040
EM 147 (94–235) 91 (53–111) 0.005 39 (21–59) 0.000 0.008
EMRA 4 (1–31) 4 (2–19) 0.688 2 (1–5) 0.107 0.105
Th1 27 (15–59) 28 (15–35) 0.632 8 (4–20) 0.000 0.069
Th2 45 (30–69) 34 (27–43) 0.124 14 (10–27) 0.000 0.063
Th17 60 (35–81) 31 (29–37) 0.013 17 (10–36) 0.000 0.029
Regulatory 43 (29–63) 24 (20–29) 0.008 12 (9–21) 0.000 0.026
Il2R+ 17 (9–21) 10 (7–14) 0.052 6 (3–9) 0.000 0.063
CD3+ CD56+
cells
45 (18–77) 47 (15–85) 0.903 29 (8–49) 0.035 0.191
NK cells 226 (143–300) 127 (85–197) 0.017 81 (60–166) 0.000 0.097
CD56+ CD16
+
193 (114–270) 102 (76–173) 0.021 68 (51–130) 0.000 0.097
CD56dim
CD16bright
15 (11–20) 10 (5–13) 0.013 4 (3–12) 0.001 0.281
CD56bright
CD16dim
15 (10–19) 8 (6–12) 0.009 4 (2–7) 0.000 0.003
B cells 211 (149–274) 59 (43–87) 0.000 71 (42–161) 0.000 0.418




8 (5–13) 1 (1–2) 0.000 1 (1–2) 0.000 0.985
Class switch
memory
25 (14–43) 9 (5–11) 0.000 6 (5–11) 0.000 0.985
Transitional 10 (6–17) 3 (1–6) 0.003 2 (1–4) 0.000 0.749
Note: Significance level are given for comparison between patients with light vs. healthy controls (p1), patients with severe COVID-19 vs. healthy controls
(p2), and patients with moderate vs. severe COVID-19 (p3).
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was observed on CD56bright CD16dim (cB: 0.902, p = 0.008) and
CD56dim CD16bright (cB: 0.873, p = 0.018) NK cells.
4 | DISCUSSION
In this prospective study, we analyzed lymphocyte subsets of
33 elderly patients with different degrees of COVID-19 severity. In
univariate analysis we found lower counts of total lymphocytes and all
their subsets, with the exception of CD4+ and CD8+ EMRA cells as
well as late and terminal effector T helper cells, in patients with severe
COVID-19. In patients affected by moderate COVID-19, a similar
trend was found for most analyzed cell populations, although this did
not always reach statistical significance.
Reduction of lymphocyte numbers in patients with COVID-19 is
well known.13–15 Usually, the human immune system reacts by induc-
ing proliferation of lymphocytes during the acute phase of viral infec-
tions including cytomegalovirus,16 Epstein Barr virus,17 and also
TABLE 3 Median cell counts of lymphocytes and their subsets of total cohort including COVID-19 patients and healthy controls (n = 83),
deviation of cell counts dependent on age over lifetime, and p value
Median cell count/μl (interquartile range) Relative cell count deviation per 10 years p value
Total lymphocytes 1490 (968–2071) 12.5% <0.001
CD3+ cells 961 (529–1354) 14.1% <0.001
CD8+ cells 231 (138–422) 19.1% <0.001
Naive 49.6 (14–109) 38.8% <0.001
Memory 83 (39–143) 19.6% <0.001
CM 21 (7–44) 21.1% <0.001
EM 65 (29–120) 18.3% <0.001
EMRA 49 (21–108) +3.5% 0.541
Early 153 (54–213) 29.5% <0.001
Intermediate 15 (7–28) 14.5% 0.002
Late 47 (24–121) 4.0% 0.49
Exhausted 65 (40–114) 9.6% 0.015
Terminal effector 23 (11–79) 7.0% 0.286
Regulatory 0.3 (0.1–0.6) 13.3% 0.109
Il2R+ 0.4 (0.2–0.8) 27.6% 0.0.956
CD4+ cells 574 (320–937) 14.8% <0.001
Naive 221 (114–372) 21.5% <0.001
Memory 338 (168–537) 14.2% <0.001
CM 219 (92–344) 16.0% <0.001
EM 98 (53–181) 13.0% 0.003
EMRA 3 (1–19) 12.9% 0.215
Th1 21 (11–44) 6.1% 0.326
Th2 34.0 (19–52) 5.1% 0.439
Th17 38.8 (24–72) 11.0% 0.064
Regulatory 30 (20–52) 12.5% <0.001
Il2R+ 11 (6–19) 18.2% <0.001
CD3+ CD56+ cells 34 (17–67) 3.5% 0.549
NK cells 171 (93–269) 13.6% <0.001
CD56+ CD16+ 137 (80–240) 13.4% <0.001
CD56dim CD16bright 13 (7–19) 17.8% <0.001
CD56bright CD16dim 11 (6–17) 19.0% <0.001
B cells 166 (76–238) 14.4% <0.001
Naive 93 (38–149) 23.4% 0.001
Memory non-class switch 5 (1–10) 24.0% 0.001
Memory class switch 15 (7–33) 10.8% 0.046
Transitional 6 (3–11) 79.3% <0.001
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F IGURE 2 Age dependent distribution of cell counts and median decrease over lifetime (black line, 95% confidence interval in gray) of total
lymphocytes (A), CD8+ lymphocytes (B), naïve CD8+ lymphocytes (C), and early CD8+ lymphocytes (D) in patients with moderate COVID-19
(bright red), severe COVID-19 (red), and healthy controls (black), respectively. Symbols: circle = female gender, triangle = male gender
F IGURE 3 Impact of moderate/severe COVID-19 (bright red/red) as well as gender (blue) and age (green) on lymphocyte counts were
estimated in multivariate analysis. Levels of COVID-19 columns indicate percentage deviation from normal values of healthy controls. Blue
columns indicate mean percentage influence of female gender. Levels of age columns reflect percentage deviation per 10 years. Black bars in
columns present 95% confidence interval
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human immunodeficiency virus.18 Only few virus infections like avian
influenza virus H5N1,19 respiratory syncytial virus,20 or swine foot-
and-mouth disease virus21 are associated with generalized
lymphocytopenia. Different types of coronaviruses belong to this
group and likewise present with lymphocytopenia.22, 23 The patho-
physiology of lymphocytopenia in patients with COVID-19 has not
yet been elucidated. The transient lymphocyte decrease might mainly
caused by T cell recruitment to sites of infection, especially to the
lungs, leading to extensive lymphocyte infiltration.24, 25 After recovery
from COVID-19, normal lymphocyte values can be found again with-
out quantitative restrictions of any lymphocyte subsets, as we have
shown recently.12
In our study, multivariate analysis confirmed the independent
negative effect of COVID-19 on total lymphocyte counts, and on
most lymphocytic subsets as seen in univariate analysis. Women had
higher CD3+ cells than men, which was mainly due to the higher
number of T helper cells. The positive influence of female gender on
the level of CD4+ cells in human peripheral blood is well known.9, 10
Aging mainly has a negative effect on the number of CD3+ and CD8
+ cells,26 which was also observed in our study, where at least the
number of CD8+ cells decreased with age. The used fitted multivari-
ate linear regression analysis was able to identify this significant
difference, although the distribution of age between our COVID-19
cohort and the control group was statistically different.
Looking at detailed T cell subsets in our analysis, naïve CD4+ and
CD8+ were significantly influenced by gender as well as age,
and COVID-19 had little or no effect on number of these cell counts. In
particular, the number of naïve T cells decreases during life27–29 which
can be explained by an increasing tissue involution of the thymus and
the accompanying dysregulation of the thymic epithelial cell architec-
ture.30, 31 This aging effect was the only cell-reducing factor for naïve
CD8+ cells in the multivariate analysis of our study, whereas COVID-19
did not even negatively affect the level of this subset in the severe
affected patient cohort as might have been expected from the uni-
variate analysis. Early and CM cytotoxic T lymphocytes also decreased
with age in our study, whereas only severe COVID-19 was found to be
a reducing factor for early CD8+ cells. Within CD4+ subsets, numbers
of CM, EMRA, THC2, and regulatory CD4+ cells were also reduced by
aging, which amplified the reducing effect of severe COVID-19.
Numbers of total B cells and their subsets were found to be
reduced in moderate as well as severe COVID-19 patients as
described before,8, 24 with an additional aging effect for transitional B
cells. Counts of circulating NK cells and subsets were only reduced in
severe COVID-19 patients in our study as reported in multiple studies
probably due to migrations into SARS-CoV-2 infected tissues mainly
in the lungs.32–34
Our study has some limitations: the focus of our investigation
was centered on adults. Thus, our results are probably not be transfer-
able to children infected by SARS-CoV-2 who may have specific age
and gender effects on lymphocytes and their subsets. Furthermore,
the number of participants is limited especially in the subcohort of
moderate COVID-19.
In summary, our study confirms the decrease in the total number
of lymphocytes, cytotoxic and helper T cells, B and NK cells, and
almost all their subsets, especially in COVID-19 patients with severe
course. Since severe COVID-19 mainly affects elderly patients, it is
important to consider the additional effect of aging which leads to
reduction in naïve CD4+ and CD8+ cells. Similarly, gender must be
taken into account given the diminished decreases of CD3+ and
CD4+ lymphocyte counts in female compared to male COVID-19
patients.
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